Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study

PURPOSE: The use of growth factors adds considerable expense and some toxicity to adjuvant breast cancer chemotherapy. We tested the feasibility and safety of omitting routine peg-filgrastim use during the paclitaxel portion of the dose-dense doxorubicin-cyclophosphamide–paclitaxel regimen. PATIENTS...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Vaz-Luis, Ines, Barroso-Sousa, Romualdo, Di Meglio, Antonio, Hu, Jiani, Rees, Rebecca, Sinclair, Natalie, Milisits, Lindsey, Leone, Jose Pablo, Constantine, Michael, Faggen, Meredith, Briccetti, Frederick, Block, Caroline, O'Neil, Kelly, Partridge, Ann, Burstein, Harold, Waks, Adrienne G., Trippa, Lorenzo, Tolaney, Sara M., Hassett, Michael, Winer, Eric P., Lin, Nancy U.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2020
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7367545/
https://ncbi.nlm.nih.gov/pubmed/32330102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02484
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki